141 related articles for article (PubMed ID: 24165977)
1. Can expedited FDA drug approval without expedited follow-up be trusted?
Carpenter D
JAMA Intern Med; 2014 Jan; 174(1):95-7. PubMed ID: 24165977
[No Abstract] [Full Text] [Related]
2. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
Wallach JD; Ramachandran R; Bruckner T; Ross JS
JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
[TBL] [Abstract][Full Text] [Related]
5. Parsing clinical success rates.
Mullard A
Nat Rev Drug Discov; 2016 Jun; 15(7):447. PubMed ID: 27357012
[No Abstract] [Full Text] [Related]
6. The statin wars.
McKillop T
Lancet; 2003 Nov; 362(9394):1498. PubMed ID: 14602449
[No Abstract] [Full Text] [Related]
7. Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012.
Crossley JR; Tan TP; Smith KH; Ross JS; Merenstein DJ
J Gen Intern Med; 2018 Sep; 33(9):1431-1432. PubMed ID: 29777429
[No Abstract] [Full Text] [Related]
8. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
[TBL] [Abstract][Full Text] [Related]
9. Accelerated approval of drugs: ethics versus efficacy.
Chary KV; Pandian K
Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403
[TBL] [Abstract][Full Text] [Related]
10. The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.
Angelis A; Baltussen R; Tervonen T
Am J Public Health; 2021 Feb; 111(2):205-208. PubMed ID: 33439703
[No Abstract] [Full Text] [Related]
11. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
12. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
13. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
14. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
Wallach JD; Egilman AC; Ross JS; Woloshin S; Schwartz LM
J Gen Intern Med; 2019 Apr; 34(4):492-495. PubMed ID: 30543020
[No Abstract] [Full Text] [Related]
15. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
16. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
17. A drug is not a drug is not a drug: a commentary.
Struijker Boudier HA
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
[No Abstract] [Full Text] [Related]
18. Defining, monitoring and combining safety information in clinical trials.
Enas GG; Goldstein DJ
Stat Med; 1995 May 15-30; 14(9-10):1099-111; discussion 1113-6. PubMed ID: 7569503
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
Roth-Cline MD
Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
[No Abstract] [Full Text] [Related]
20. Expedited approval programs at the Food and Drug Administration.
Begg CB; Ellenberg SS
Clin Trials; 2018 Jun; 15(3):217-218. PubMed ID: 29871506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
